MOVEMBER CAMPAIGN RAISES $20K FOR MEN’S HEALTH …surgery.duke.edu/sites/surgery.duke.edu/files/field/attachments/Duke Urology...In 2011, Dr. Baker joined the Cleveland Clinic as

MOVEMBER CAMPAIGN RAISES $20K FOR MEN’S HEALTH AWARENESS

Urology Welcomes Male Fertility Specialist p. 3

ALSO INSIDE:

Duke

Urology UpdateS P R I N G 2 0 1 7

Long-term Care for Patients with Spina Bifida p. 8

Duke Urology Ranks 9th Nationally in U.S. News & World Report p. 7

C L I N I C A L

High-Intensity Focused Ultrasound

for Prostate Tissue Ablation

O n October 7, 2016, the first application of a newly approved technology for prostate ablation

was utilized to treat a prostate cancer patient at Duke Hospital. This represented the culmination of 10 years of clinical research and participation in a clinical trial investigating high-intensity focused ultrasound (HIFU) in the treatment of prostate tissue.

This noninvasive therapy utilizes focused ultrasound energy applied to prostate tissue through the rectum. It is well tolerated as an outpatient treatment. In the clinical trial, 135 subjects were treated nationally, with 27 subjects at Duke. Morbidity was minimal and all subjects experienced declines in prostate

MALE FERTILITY SPECIALIST KAREN BAKER, MD, JOINS DUKE UROLOGY

D r. Karen Baker joined the Duke Urology faculty in 2017 to provide comprehensive surgical

and medical male fertility care. Dr. Baker works closely with the Duke Fertility Center to ensure couples receive a complete male evaluation and understand their range of options before embarking on a reproductive plan.

Dr. Baker earned her undergraduate degree at Dartmouth College in 1991 and her medical degree from the Uniformed Services University of the Health Sciences in Bethesda, MD, in 1995. She completed her internship and urology residency at Madigan Army Medical Center in 2001. Dr. Baker completed three overseas tours, earned her Basic Parachutist and Expert Field Medical Badge, and was awarded the Legion of Merit before retiring from the U.S. Army as a colonel in 2016. During her tenure at Madigan, she served in a variety of roles, including teaching faculty, Chair of Specialty Care Quality

volume and extent of prostate tumor. After trial completion in 2014, the FDA cleared this technology in October 2015 as a surgical tool for the treatment of prostate tissue. Duke Urology led the national trial, serving as national principal investigator, under the direction of Cary N. Robertson, MD, FACS. This technology has been highlighted as a focal therapy approach for selective partial prostate tissue ablation in selected patients. This has the advantage of preserving urinary anatomy and urinary control with minimal impact on erectile function. A case example is available for review in the Duke online medical newsletter, Clinical Practice Today, presented by Duke Health in the April 26, 2016, edition.

Management group, Chair of the Material Standardization Committee, voting member of the hospital Executive Board of Directors, and Chief of the Urology Service.

In 2011, Dr. Baker joined the Cleveland Clinic as a male fertility fellow and was subsequently awarded the Crile Research Fellowship from 2012 to 2013. Her projects included the use of nanoparticles in testicular disorders, impact of reference values on male infertility referrals patterns, outcomes after varicocelectomy, microsurgical fertility techniques, and predictive models for genetic testing in male infertility.

Dr. Baker’s research interests include surgical outcomes of microsurgical vasectomy reversals, varicocelectomy, and sperm retrieval; impact of medical comorbidities on male fertility; pathogenesis of subfertility in diabetes and obesity; and medical management of male infertility.

F RO M T H E C H I E F

Welcome to our 2017 Spr ing Newsletter. Duke Urology continues to thrive. We welcome

our newest faculty member Karen Baker, MD, who recently completed twenty years of service in the Army. Dr. Baker will oversee our infertility program and support male infertility issues in our Urology Cancer Survivorship program. In addition, we have three Fellows this year who have excelled both clinically and in research. Vignettes of Drs. Madden-Fuentes, Longo, and Wollin demonstrate the breadth of our fellowship programs in Reconstructive Urology, Urologic Oncology and Endourology / Stone Disease.

Our Duke Urology Residents are leaders in both academics and community service. Doctors Granieri and Fantony were presented with the Southeastern Section of the AUA Humanitarian Award for their work with the Duke Urology Movember program. This year, we raised close to $20,000 to support the Movember campaign. Speaking of our Residents, the E. Everett Anderson Resident Educational Fund was established to support Duke Urology Resident education. A number of you have contributed to this important educational initiative. I would ask all of our DYSURIC members who have benefited from the residency program to support this crucial effort. All funds are used to provide educational tools and travel expenses for current Residents.

Clinically, Duke Urology remains a medical center leader in care redesign and quality improvement. Our urologic oncology group headed by Dr. Michael Ferrandino is finalizing care redesign for radical prostatectomy, radical nephrectomy, and radical cystectomy. These clinical care pathways combined with the ERAS protocols should help improve the patient care experience while providing superior results. Dr. Chuck Scales, who leads our QI and Patient Safety initiatives, reports on our progress in these areas.

In addition, our outpatient clinics, overseen by Dr. Mike Lipkin, have been highlighted by the health system as a cohesive and efficient group providing optimal outpatient care for our urology patients. To round out our clinical focus, Cary Robertson reports the recent launch of HIFU to manage patients with early stage prostate cancer.

Our pediatric urology group continues to be a leader in managing patients with spina bifida. A recent report from Maryellen Kelly, DNP, CPNP, who attended the national spina bifida meetings, demonstrates the extent of Duke Pediatric Urology’s clinical and

research expertise. Finally, Dr. Brant Inman highlights our continued efforts in Duke Urology’s research program. A large PSA specimen biorepository, started by David Paulson in 1987, continues to be a source of excellent research opportunities, ultimately leading to better care for our patients with prostate cancer.

As always, we greatly appreciate your support of Duke Urology and hope to see you at the upcoming AUA Meeting in Boston or at one of our upcoming educational

Glenn M. Preminger , MD

M E S S A G E

events. Please be sure to mark your calendar for the 50th anniversary of our Duke Urologic Assembly meeting, which will be held 5-8 April, 2018 in Hilton Head, S.C. Ralph de Vere White, previous chairman of Urology at UC Davis and proud DYSURIC will be our featured speaker for the meeting. We encourage all of our DYSURIA members to support this important educational event.

All the best,

GlennD U K E U R O L O G Y 03

Dr. Preminger meets with patient Robert Lontz to discuss treatment options for chronic kidney stones. Read more at DukeHealth.org. Photo credit: Shawn Rocco.

The research potential at Duke and its reputation for excellence in care make this an exciting place to be. At the Fertility Center, couples can meet their reproductive goals in an environment where they are most comfortable, with a plan that feels right for them. The addition of a male fertility specialist furthers our goal of providing comprehensive reproductive care to patients in the area and beyond.”

Cary Robertson, MD

“Karen Baker, MD

D rs. Joseph Fantony and Michael Granieri were recognized for their humanitarian efforts in promoting

prostate cancer awareness, fundraising, and men’s health in our community with the Inaugural Humanitarian Award of the Southeastern Section of the American Urologic Association.

Both Drs. Granieri and Fantony have a longstanding history of humanitarian service. In medical school, Dr. Michael Granieri whet his appetite for community-based prostate cancer screening events through his work with Dr. William Catalona and the Prostate Cancer Foundation. In addition, he made an impact in the global healthcare community through his primary care and urology-based mission trips with Dr. Christopher Gonzalez.

Similarly, Dr. Fantony was charged with the staffing and administration of one of the largest community free clinics in Worcester County during his medical school training. Furthermore, he has been a regular volunteer at the local Special Olympics events for years. It is remarkable that these young physicians not only make a daily impact on the lives of their patients, but also have the intrinsic motivation to go one step further and become role models in our community.

When Dr. Granieri arrived at Duke Urology in 2012, he initiated a local Movember campaign as a great way for the Division of Urology to have some fun and raise awareness for men’s health issues. Initially, fundraising efforts were limited to those within the division and other small interested groups throughout the hospital. Fundraising efforts reached approximately $2000 in 2012 and 2013. In 2014, Granieri teamed up with co-resident Fantony to spearhead a fundraising initiative involving not only the entire medical center, but also the Duke Community at-large.

C L I N I C A L

DUKE RESIDENTS WIN THE SOUTHEASTERN SECTION AUA HUMANITARIAN AWARD

Over the last year, Clinic 1G Urology has worked hard to build a culture of teamwork. With support from

our medical director, our clinic and division leadership, clerical and nursing staff, and team of providers, we have improved our patient experience metrics, communication, and engagement. Our Balanced Score Card results have improved, and nearly every metric surpasses our year-to-date goal.

A key to our success has been the combination of the newer staff’s enthusiasm with the commitment to precepting and teaching by our more experienced team members. Clinical and clerical teams get together monthly to review patient comments, celebrate successes on our Balanced Score Card, and discuss how we can improve care, processes, and service. With weekly “What’s new Wednesday” email updates from our Clinical Team Lead, Lisa Drylie, and informal huddles in clinic to debrief and strategize, the staff works to communicate often, effectively, and with the goal to include all perspectives.

To enhance the clinic’s knowledge base in urology, physicians are very engaged in sharing their clinical expertise through quarterly in-services with the staff. Our Medical Director, Dr. Michael Lipkin, kicked off this initiative with an overview on ureteroscopy and shock wave lithotripsy for removal of kidney stones. Our newest physician, Dr. Karen

Baker, followed with an in-service on male infertility, and training on vasectomy procedures. This expanded the tools and supplies for staff to be engaged in their roles and added a sense of pride and ownership over their patient care in the clinic.

It’s not just work that helped us come together in Clinic 1G: We celebrate often for birthdays, holidays, and in recognition of improvement of our metrics. Our team dinner in March was an excellent way to step away from work and just have fun together. Our kudos board is where we can recognize each other’s efforts and say thanks. This type of fellowship has helped transform our clinic into a real community.

And there is more to do! With initiatives underway to improve communication of delays to patients, and advancing the scope of practice of the CMAs, we are striving for excellence in collaboration, and continuing to come together as a team.

SYNERGY SUCCESSL E A D S T O

I N C L I N I C 1 G

Ultimately, it is caring for our patients which drives our continued success and brings us together. Working more closely as a team helps us take better care of our patients.”

“ Dr. Michael Lipkin, Clinic 1G

Medical Director

Dr. Michael Granieri, left, and Dr. Joseph Fantony, below, spearheaded Duke’s annual Movember men’s health and prostate awareness campaigns.

Through their tireless efforts, while managing full-time clinical duties, they held prostate cancer awareness sessions at Duke Men’s Basketball games in addition to events in the Durham Community. They amplifed their fundraising efforts and awareness of their cause exponentially through strategic use of both social and community media outlets, promoting awareness of prostate cancer and men’s health on several local news channels, the campus and community newspapers, and national publications such as Scientific American. The Movember campaign raised more than $20,000 in 2016.

Caitlan Mackinnon-Patterson, MBA

Andrew C. Peterson, MD

D U K E U R O L O G Y 05

The group steps away from the clinic for a team dinner. Creating an environment of camaradarie is an active goal for the clinic.

Q U A L I T Y

07D U K E U R O L O G Y

In 2012, with the passage of the Affordable Care Act and a shift to value-based care, Duke’s senior leaders created

a committee to oversee many of the care delivery changes that would impact patients. This became the Care Redesign Committee. Care Redesign’s goal has been to improve clinical outcomes and reduce the total cost of care by supporting clinicians to redesign care processes.

Care Redesign program teams have partnered with clinical and operational leaders to improve care delivery in more than 30 clinical areas. The team has developed an approach that blends Six Sigma project management principles with clinical data, cost data, and evidence reviews to bring experts at the bedside together to identify opportunities and design solutions.

The Care Redesign Committee identified Nephrectomy and Prostatectomy patients

as potential sources for optimization. Particular goals of the project include decreasing length of stay, avoiding readmissions, improving pain control without narcotics, minimizing total cost of care, as well as standardization of pre-operative, intraoperative, and post-operative pathways across all surgeon and nursing teams. Many of the incorporated changes involve adoption of Enhanced Recovery After Surgery (ERAS) protocols such as cessation of bowel regimens and early ambulation. To date, mpressive progress has been made in regard to surgeon agreement, educational materials, nursing pathway development, and new anesthesia protocols, to name a few changes. Epic integration is currently underway via order and documentation build sets. We anticipate a full roll-out of the new Care Redesign Protocols this summer.

C A R E edesign C O M M I T T E E

Q U A L I T Y I M P R O V E M E N Tin Duke Urology

Assuring high-quality care is increasingly important to urologists, payers, and patients in today’s

healthcare environment. Duke Urology maintained its status among the Top 10 hospitals in the country for urology in the most recent US News & World rankings, which are increasingly weighted toward outcomes of urological care. In order to improve our outcomes, Duke Urology is instituting a number of efforts to measure and improve care quality.

Over the past year, Duke Urology has begun participation in the American College of Surgeons National Surgical Quality Improvement Program (NSQIP), which measures risk-adjusted outcomes among major urologic procedures such as cystectomy, nephrectomy, and prostatectomy. Gathering these data will permit not only better tracking of our own outcomes, but also allow a better comparison of our outcomes to other institutions. In addition, NSQIP will provide a standard way to assess the impact of care redesign interventions, such as the standardized care pathways being implemented for nephrectomy and prostatectomy.

On the ambulatory care side, the Duke Comprehensive Kidney Stone Center is embarking on a care redesign project to improve outcomes for patients undergoing ureteroscopy for ureteral and renal stones. An interprofessional, multidisciplinary team under the leadership of Dr. Dan Wollin and supported by Drs. Glenn Preminger, Michael Lipkin, and Chuck Scales will examine care delivery throughout every phase of the patient’s journey. The care redesign team involves nursing leadership (Lisa Drylie, RN), anesthesiology (Timothy Miller, MB, ChB), advanced practice providers (Sarah Yttri, NP), urology administration (Wendy Webster, MBA), and members of the Duke University Hospital Performance Services team (Robin Anderson, Theresa Alston-Williams and Jacquelyn Yanik). The ultimate goal of the project is to improve patient satisfaction and reduce preventable returns to the emergency department after ureteroscopy.

With efforts such as these, we plan to continue improving the outstanding care for which Duke Urology is known, and increase the Division’s leadership in this key area of urology.

Chuck Scales, MDVice Chief of

Quality Improvement & Patient Safety

Michael Ferrandino, MD

Decrease length of hospital stay

Improve pain without narcotics

Avoid readmissions

Minimize total care cost

Survival Better than average 7 / 10

Patient safety Average 4 / 5

Number of patients Very high 437 discharges

Nurse staffing Best 2.2

Nurse Magnet status

Advanced technologies Best 6 / 6

Patient services Best 9 / 9

Trauma center - -

- -

Intensivists - -

Reputation w/ specialists Excellent 13.8%

O V E R A L L S C O R E 80.9 / 100

DUKE UNIVERSITY HOSPITAL UROLOGY

NATIONAL RANK:

9TH

S C O R E C A R D

D U K E U R O L O G Y 09

R E S E A R C H

The 3rd World Congress on Spina Bifida Research and Care was held March 16-19, 2017, in San Diego,

CA. Pediatric Urology at Duke was well represented with eight presentations. Duke Urology is also a significant contributor to the National Spina Bifida Patient Registry (NSBPR), with over 400 patients enrolled. The NSBPR is funded and managed by the CDC and provides the framework for a systematic approach to improve the care at clinics serving the spina bifida population nationally. Over 7000 patients enrolled are enrolled at the 21 clinics. Research carried out with data from the NSBPR was highlighted throughout the entire three-day program in focused sessions ranging from neurosurgery to genetics to quality of life.

John Wiener, MD’s podium presentations focused largely on bowel and bladder continence outcomes. When compared to pediatric patients, adult patients tend to have better urinary continence rates in clinics that participate in the NSBPR. Bowel continence rates were also higher in adult and adolescent populations than in children under age 11. An association between bowel continence and increased education attainment and job employment was also revealed.

Additionally, Dr. Wiener presented an examination of the age distribution of surgical procedures. This revealed

a large variance in the age and genre of surgery needed. Overall, patients with myelomeningocele had a higher prevalence of less favorable health outcomes than non-myelomeningocele diagnoses within the NSBPR.

Patients with spina bifida have benefited from increased knowledge of their disease progression and the development of novel care practices. This has led to an increased life expectancy, with an estimate that over 75% of patients with spina bifida will now survive into adulthood. This has brought about a challenge in finding quality adult-centered care for aging patients with this congenital disorder. Maryellen Kelly, DNP, CPNP, presented results from a national survey of existing transitional care practices in spina bifida clinics in the U.S. Most clinics do not have written protocols for transitioning patients to adult-centered care. Clinics also self-report that they don’t commonly assess a patient’s readiness for transition, nor do they confirm that a transition has occurred. Most clinics consistently do

SPINA BIFIDA

STATISTICS IMPROVING CARE FOR

SPINA B IF IDA In 1987, prostate specific antigen (PSA) was first marketed as an FDA-approved test for prostate cancer. PSA testing became very popular and achieved rapid uptake despite a paucity of

high-quality data supporting its use. Medical centers around the U.S., including Duke University Medical Center (DUMC), began offering PSA testing as a clinical test available to men with prostate cancer or at risk of developing prostate cancer.

The Division of Urology at Duke acquired the ability to perform the serum PSA testing in the late 1980s through the purchase of capital equipment, and performed the PSA test for DUMC from within clinic 1G of the Duke South Clinics. Processing of samples, generation of result reports, billing for the test, and quality assurance procedures were all the responsibility of the Division of

Urology. Since the clinical utility and error rate of the PSA test was not known with certainty at that time, the Chief of Urology (Dr. David Paulson) had the foresight to establish a policy that all serum remaining in the blood collection tube after a serum PSA test

would be banked for future test validation and study. In the late 1990s, serum PSA testing was transferred to the Department of Pathology for health system centralization reasons, and the Chair of Pathology (Dr. Salvatore Pizzo) elected to continue storing these clinical serum samples, following the clinical policy of Dr. Paulson. In December 2012, the accumulated evidence regarding the safety of PSA testing and the rising cost of continued storage of these samples resulted in the end of systematic PSA serum banking. However, the historical clinical serum banking policies have resulted in a biobank of nearly 150,000 serum tubes banked from approximately 1990 until 2012, occupying 10 large -80°C freezers on campus.

The PSA serum bank is presently guarded and maintained by the Division of Urology and has resulted in several IRB-approved research protocols to access the PSA serum bank for the study of novel diagnostic tests and biomarkers for cancer and other diseases. These protocols include both industry-academic partnerships and investigator-initiated studies funded by grants. As current custodian of these samples, I think it is fair to say that Duke Urology looks forward to decades of research, both homegrown and in collaboration with other investigators, developing and validating novel biomarkers of human disease.

assess adolescents for their ability to independently perform preventative care, bowel and bladder management regimens, and list their medications. A large obstacle for these patients, families, and their medical providers is the lack of adult providers willing and confident in their ability to provide medical and surgical care to this aging population.

We recognize that the increasing age of our patients will influence healthcare expenses. Jonathan Routh, MD, MPH, presented on the economic implications of modern spina bifida care. In 2010, the economic impact of spina bifida was at least $1.79 billion on the healthcare system. It is thought that this is a gross underestimation of the true cost of healthcare for this population, as it does not include outpatient care visits, medications, outpatient surgeries, or societal costs. Interestingly, over a third of patients who presented to the emergency room for care were admitted, and the majority had public insurance.

The pediatric urology team plans to continue to be a leader in spina bifida care and research. In 2016, our team recruited 58 new patients and interviewed 230 existing patients for the NSBPR. Duke had the highest number of new patients enrolled for 2016 and one of the highest numbers of return visits in the U.S. Our research this year will contribute to defining gold standard bowel management regimens and improved urologic care for both children and adults.

PATIENTS WITH

A large obstacle for patients, families, and medical providers is the lack of adult care providers willing and confident in their ability to provide medical and surgical care to the aging population affected by spina bifida.”

“

1500 infants are born with spina bifida in the U.S. each year.

18% of babies with spina bifida have more than 3 hospital stays in their first year.

Medical costs to treat one infant with spina bifida range from $21.9k all the way to $1.35m for just one year.

More than 75% of patients with spina bifida have a full life expectancy. 75%

PSA SERUM BIOBANK

Duke Urology looks forward to decades of

research, both homegrown and in collaboration with

other investigators, develop-ing and validating novel bio-markers of human disease.”

“Maryellen Kelly, DNSC, RN

Brant Inman, MD

Data from the Centers for Disease Control and Prevention.

D U K E U R O L O G Y 011

THOMAS LONGO, MD

DANIEL WOLLIN, MD

Dr. Tom Longo completed medical school and residency at the University of Nebraska Medical center and joined Duke for his Society of Urologic Oncology Fellowship in 2015. During his fellowship, he has been involved with projects investigating therapeutic hyperthermia in bladder cancer, comparative oncology in bladder cancer (canine and human), and alternate RNA splicing in prostate cancer amongst races. Following the completion of his fellowship this summer, he will be joining our staff at Duke. His wife and three children are delighted to be staying in the Triangle.

RAMIRO MADDEN-FUENTES, MDDr. Ramiro (Joe) Madden-Fuentes obtained his medical degree from Baylor College of Medicine and joined Duke Urology in 2010. He completed residency in June 2016 and continued at Duke Urology as the Reconstructive Urology and Cancer Survivorship fellow. During his training at Duke, he has participated in basic science and clinical research. His research during fellowship has been focused on treatment and management of urinary sequelae of prostate cancer therapies. After completion of fellowship, he will be joining Concord Hospital in Concord, N.H., where he will focus on male reconstruction and participate in the education of Dartmouth residents.

Dr. Daniel Wollin was born in Massachusetts, where he completed his undergraduate education at Williams College. After a stint in Chicago for medical school, he completed his urologic residency at New York University. He has trekked down to the south to complete a fellowship in endourology, metabolic stone disease, laparoscopy, and robotic surgery. In his spare time, he enjoys cooking and playing guitar. His research interests focus on medical prevention of nephrolithiasis and in vitro evaluation of surgical treatment modalities and novel devices. He lives in Carrboro with his wife, who is currently a Head and Neck Surgical Oncology fellow at the University of North Carolina.

F E L L O W H I G H L I G H T S E D U C A T I O NR E S E A R C H

GRANTS, AWARDS, & RECOGNITION DR. PREMINGER RECIEVES LIFETIME ACHIEVEMENT AWARD

Duke Urology is pleased to announce that the Research on Calculus Kinetics (ROCK) Society presented a Lifetime Achievement award to Glenn Preminger, MD.

Dr. Preminger was recognized for his significant contributions to kidney stone research and for his mentoring of urologists in the field of kidney stones.

Congratulations, Dr. Preminger!

From left to right: Drs. Daniel Wollin, Jodi Antonelli, Michael Lipkin, Glenn Preminger, and Pei Zhong.

Brant A. Inman, MD, Cary N. Robertson Associate Professor of Urology Surgery, Vice Chief of Urology:

CLINICAL TRIALS• The Efficacy of the Bladder EpiCheck for

Detection of Recurrent Urothelial Cell Carcinoma: A Multicenter, Prospective Blinded Pivotal Study from Nucliex Ltd.

• A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel on Ablation of Upper Urinary Tract Urothelial Carcinoma from UroGen Pharma Ltd.

• A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer from FKD Therapies Oy.

• A Phase Ib/II, open-label study of the safety and pharmacology of Atezolizumab administered with/without BCG in patients with High Risk Non-Muscle-Invasive Bladder Cancer from Genentech, Inc.

RESEARCH• Therapeutic Targeting of B7-H3 to

reverse prostate cancer treatment resistance from the Department of Defense

• Identification of carcinogen-induced mutational signatures in human and canine bladder cancer from the DCI and NCSU Consortium for Canine Comparative Oncology

• Duke- Africa Prostate Study: Alternative Splicing from the Duke Cancer Institute

Michael E. Lipkin, MD, MBA, Associate Professor of Urologic Surgery, Chief of the Clinic:

CLINICAL TRIAL• A Phase 2, Multicenter, Randomized,

Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of ALLN-177 Treatment Over 28 Days in Patients with Secondary Hyperoxaluria and Kidney Stones from Allena Pharmaceuticals

Judd W. Moul, MD, FACS, James H. Semans, MD Professor of Surgery, Professor in Anesthesiology, Director, Duke Prostate Center:

RESEARCH• A Prospective Observational Cohort

Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States from Astellas Pharma Global Development, Inc.

Andrew C. Peterson, MD, Professor of Surgery, Director of the Urology Residency Program and the Reconstructive Urology and Genitourinary Cancer Survivorship Fellowship:

FELLOWSHIP• Genitourinary Cancer Survivorship

Fellowship from Boston Scientific Corporation

Thomas J. Polascik, MD, Professor of Surgery, Director of the Urologic Oncology Fellowship:

CLINICAL TRIAL• “A Phase 3 Study to Evaluate the Safety

and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men with Biopsy Proven Low-Grade Prostate Cancer who are Candidates for Active Surveillance (proSPECT-AS) from Molecular Insight Pharmaceuticals, Inc.

FELLOWSHIP• Urology Fellowship Agreement from

HealthTronics Surgical Services, Inc.

RESEARCH• Duke Cancer Institute Multidisciplinary

Active Surveillance (DUCIMAS) Prostate Cancer Cohort Study from Myriad Genetics

J. Todd Purves, MD, AB, PhD, Associate Professor of Surgery:

CLINICAL TRIAL• BOTOX in the Treatment of Urinary

Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age from Allergan, Inc.

FELLOWSHIP• Purves/Inouye AUA Resident Award from

the AUA Foundation

Edward N. Rampersaud Jr., MD, Assistant Professor of Surgery:

CLINICAL TRIALS• A Phase II study of Sporadic

Angiomyolipomas (AMLs) Growth Kinetics while on Everolimus Therapy from Fox Chase Cancer Center

• An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered Intuvax pre-nephrectomy followed by Sunitinib post-nephrectomy, compared to Sunitinib post-nephrectomy in metastatic renal cell carcinoma patients from Immunicum AB

Jonathan C. Routh, MD, MPH, Associate Professor of Surgery and Pediatrics:

RESEARCH• Defining the Impact of Differences of Sex

Development on Patients and Families from the Josiah Charles Trent Memorial Foundation

• Novel Preference Evaluation for Treatment of Vesicoureteral Reflux from the AUA Foundation & Urology CARES Foundation Herbert Brendler, MD Research Fund

Charles D. Scales, MD, Assistant Professor of Surgery:

CLINICAL TRIAL• Urinary Stone Disease Research Network:

Scientific Data Research Center form the National Institutes of Health

RESEARCH• Bladder Cancer in Older Adults - Treatment

and Outcomes from AstraZeneca Pharmaceuticals, LP

John S. Wiener, MD, Professor of Surgery and Pediatrics:

RESEARCH• Clinical Genomics Study: Recruitment and

Return of Clinical Actionable Items from the National Institutes of Health

• National Spina Bifida Patient Registry and Urologic Management of Young Children with Spina Bifida - Duke Project from the Centers for Disease Control and Prevention

• Urologic Management to Preserve Renal Function Protocol - Duke Project from the Centers for Disease Control and Prevention

DUKE HEALTH FELLOWS PROGRAMThe Duke Health Scholars and Duke Health Fellows Program was created with a transfer of funds from the Duke University Health System, and it supports the research efforts to enhance the academic success of early

to mid-career clinician-scientists in School of Medicine clinical departments. Department chairs nominate faculty, and the Dean’s research leadership team selects recipients.

Jonathan C. Routh, MD, MPH, and J. Todd Purves, MD, AB, PhD, were named Duke Health Fellows. Dr. Purves received funding in the amount of $150,000 to support his continuing research.

J. Todd Purves, MD, AB, PhD

FUNDRAISING

EE ANDERSON RESIDENT EDUCATION FUND

Since the inception of the EE Anderson Resident Education Fund in 2015, 15-19 residency program alumni have

contributed each year, helping us raise $33,000 over the past three years.

These monies are greatly appreciated to allow us to continue to provide our current residents with the best possible educational experience through the purchase of teaching materials and travel to scientific meetings.

We have been moved by some of your accompanying notes about how training at Duke was so important in your careers. We invite all DYSURICs to share how training in the Duke Urology program defined you, and

2 0 1 519 Donors

$18,200

2 0 1 615 Donors

$7,500

2 0 1 719 Donors

$7,995

$33,69553 Donors

TOTALDONATIONS:

Duke South, White Zone, Room 1571-ADUMC 3707 Durham, NC 27710

First Class MailU.S. PostagePAIDDurham, NCPermit No. 60

Cl ick. L ike. Fol low. Watch.

surgery.duke.edu/urology Duke Surgery @DukeUrology Duke Surgery

John Wiener, MD

50thannual

DUKE UROLOGIC ASSEMBLY

SAVE THE DATE

April 5 - 8, 2018

Omni Hilton Head Oceanfront Resort

Hilton Head, S.C.

to contribute to increasing the proportion of our many trainees. Please help us to honor the legacy of Everett Anderson and to ensure that Duke continues to train tomorrow’s leaders in urology.

A gift to the E.E. Anderson Fund provides professional development and research opportunities for trainees.

You can make a donation quickly and securely by visiting supportmedtraining.duke.edu, and clicking Urology under the Department of Surgery. Or, contact

Marcy Romary, Senior Director of Development919-748-0745, [email protected]